Tumor Biology

, Volume 34, Issue 1, pp 493–504 | Cite as

Adiponectin (ADIPOQ) rs2241766 G/T polymorphism is associated with risk of cancer: evidence from a meta-analysis

  • Wei Zhou
  • Yi Liu
  • De-Wu Zhong
Research Article


Associations between adiponectin (ADIPOQ) genetic polymorphisms (rs2241766 G/T and rs266729 G/C) and cancer risk have been extensively studied in the past decade, while conflicting results were reported. Therefore, this study would explore the associations by using a meta-analysis. The databases of Medline, Embase, and Wangfang were retrieved, and the latest updated time was 1 August 2012. Effect sizes of odds ratio and 95 % confidence interval (OR and 95 % CI) were calculated by using a fixed- or random-effect model. A total of 12 studies with 10,368 participants were identified for association between ADIPOQ rs2241766 G/T and risk of cancer, and ten studies with 12,665 participants were for association between ADIPOQ rs266729 G/C and risk of cancer. Overall combined analyses indicated that neither ADIPOQ rs2241766 G/T nor rs266729 G/C was associated with risk of cancer incidence (OR (95 % CI), 0.89 (0.61–1.30) for GG vs. TT and 0.94 (0.83–1.06) for G carriers vs. T carriers for rs2241766 G/T; 0.99 (0.85–1.16) for GG vs. CC and 0.96 (0.87–1.06) for G carriers vs. C carriers for rs266729 G/C). When stratified analyses were conducted according to the participants’ ethnicity, sources of controls, types of cancer, and sample size, we found that G allele of ADIPOQ rs2241766 G/T was significantly associated with decreased risk of cancer based on population-based case–control studies (OR (95 % CI), 0.65 (0.50–0.85) for GG vs. TT and 0.88 (0.79–0.98) for G carriers vs. T carriers). In contrast, there was no association between rs266729 G/C polymorphism and risk of cancer when subgroup analyses were conducted. In summary, this meta-analysis indicated that ADIPOQ rs2241766 G/T rather than rs266729 G/C polymorphism was closely associated with risk of cancer development.


Adiponectin Gene polymorphism Cancer Meta-analysis 


Conflicts of interest



  1. 1.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.PubMedCrossRefGoogle Scholar
  2. 2.
    Roder DM. The epidemiology of gastric cancer. Gastric Cancer. 2002;5 Suppl 1:5–11.PubMedCrossRefGoogle Scholar
  3. 3.
    Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol. 2006;12:17–20.PubMedGoogle Scholar
  4. 4.
    Mao WM, Zheng WH, Ling ZQ. Epidemiologic risk factors for esophageal cancer development. Asian Pac J Cancer Prev. 2011;12:2461–6.PubMedGoogle Scholar
  5. 5.
    Correa P. Human gastric carcinogenesis: a multistep and multifactorial process—first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res. 1992;52:6735–40.PubMedGoogle Scholar
  6. 6.
    Li, H., Da Li, Q., Wang, M. S., Li, F. J., Li, Q. H., Ma, X. J. et al. Smoking and air pollution exposure and lung cancer mortality in Zhaoyuan County. Int J Hyg Environ Health. 2012. doi: 10.1016/j.ijheh.2012.06.003.
  7. 7.
    Yang, W. S., Wong, M. Y., Vogtmann, E., Tang, R. Q., Xie, L., Yang, Y. S. et al. Meat consumption and risk of lung cancer: evidence from observational studies. Ann Oncol. 2012. doi: 10.1093/annonc/mds207.
  8. 8.
    Dehal A, Garrett T, Tedders SH, Arroyo C, Afriyie-Gyawu E, Zhang J. Body mass index and death rate of colorectal cancer among a national cohort of U.S. adults. Nutr Cancer. 2011;63:1218–25.PubMedCrossRefGoogle Scholar
  9. 9.
    Yang P, Zhou Y, Chen B, Wan HW, Jia GQ, Bai HL, et al. Overweight, obesity and gastric cancer risk: results from a meta-analysis of cohort studies. Eur J Cancer. 2009;45:2867–73.PubMedCrossRefGoogle Scholar
  10. 10.
    Peek Jr RM, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer. 2002;2:28–37.PubMedCrossRefGoogle Scholar
  11. 11.
    Grossmann ME, Nkhata KJ, Mizuno NK, Ray A, Cleary MP. Effects of adiponectin on breast cancer cell growth and signaling. Br J Cancer. 2008;98:370–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, Nagawa H. Plasma adiponectin and gastric cancer. Clin Cancer Res. 2005;11:466–72.PubMedCrossRefGoogle Scholar
  13. 13.
    An W, Bai Y, Deng SX, Gao J, Ben QW, Cai QC, et al. Adiponectin levels in patients with colorectal cancer and adenoma: a meta-analysis. Eur J Cancer Prev. 2012;21:126–33.PubMedCrossRefGoogle Scholar
  14. 14.
    Yang WS, Tsou PL, Lee WJ, Tseng DL, Chen CL, Peng CC, et al. Allele-specific differential expression of a common adiponectin gene polymorphism related to obesity. J Mol Med (Berl). 2003;81:428–34.CrossRefGoogle Scholar
  15. 15.
    Kaklamani VG, Wisinski KB, Sadim M, Gulden C, Do A, Offit K, et al. Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. JAMA. 2008;300:1523–31.PubMedCrossRefGoogle Scholar
  16. 16.
    Cui E, Deng A, Wang X, Wang B, Mao W, Feng X, et al. The role of adiponectin (ADIPOQ) gene polymorphisms in the susceptibility and prognosis of non-small cell lung cancer. Biochem Cell Biol. 2011;89:308–13.PubMedCrossRefGoogle Scholar
  17. 17.
    He B, Pan Y, Zhang Y, Bao Q, Chen L, Nie Z, et al. Effects of genetic variations in the adiponectin pathway genes on the risk of colorectal cancer in the Chinese population. BMC Med Genet. 2011;12:94.PubMedCrossRefGoogle Scholar
  18. 18.
    Moore SC, Leitzmann MF, Albanes D, Weinstein SJ, Snyder K, Virtamo J, et al. Adipokine genes and prostate cancer risk. Int J Cancer. 2009;124:869–76.PubMedCrossRefGoogle Scholar
  19. 19.
    Beebe-Dimmer JL, Zuhlke KA, Ray AM, Lange EM, Cooney KA. Genetic variation in adiponectin (ADIPOQ) and the type 1 receptor (ADIPOR1), obesity and prostate cancer in African Americans. Prostate Cancer Prostatic Dis. 2010;13:362–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Attia J, Thakkinstian A, D’Este C. Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol. 2003;56:297–303.PubMedCrossRefGoogle Scholar
  21. 21.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  22. 22.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  23. 23.
    Liu L, Zeng F, Wang K, Huang J, Xin L, Zhu PQ. Meta-analysis of the association between VEGF-634.G > C and risk of malignancy based on 23 case–control studies. J Cancer Res Clin Oncol. 2011;137:1027–36.PubMedCrossRefGoogle Scholar
  24. 24.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRefGoogle Scholar
  25. 25.
    Tang H, Dong X, Hassan M, Abbruzzese JL, Li D. Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:779–92.PubMedCrossRefGoogle Scholar
  26. 26.
    Al Khaldi RM, Al Mulla F, Al Awadhi S, Kapila K, Mojiminiyi OA. Associations of single nucleotide polymorphisms in the adiponectin gene with adiponectin levels and cardio-metabolic risk factors in patients with cancer. Dis Markers. 2011;30:197–212.PubMedGoogle Scholar
  27. 27.
    Kaklamani VG, Sadim M, Hsi A, Offit K, Oddoux C, Ostrer H, et al. Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk. Cancer Res. 2008;68:3178–84.PubMedCrossRefGoogle Scholar
  28. 28.
    Kaklamani V, Yi N, Zhang K, Sadim M, Offit K, Oddoux C, et al. Polymorphisms of ADIPOQ and ADIPOR1 and prostate cancer risk. Metabolism. 2011;60:1234–43.PubMedCrossRefGoogle Scholar
  29. 29.
    Al-Harithy RN, Al-Zahrani MH. The adiponectin gene, ADIPOQ, and genetic susceptibility to colon cancer. Oncol Lett. 2012;3:176–80.PubMedGoogle Scholar
  30. 30.
    Partida-Perez M, de la Luz Ayala-Madrigal M, Peregrina-Sandoval J, Macias-Gomez N, Moreno-Ortiz J, Leal-Ugarte E, et al. Association of LEP and ADIPOQ common variants with colorectal cancer in Mexican patients. Cancer Biomark. 2010;7:117–21.PubMedGoogle Scholar
  31. 31.
    Dhillon PK, Penney KL, Schumacher F, Rider JR, Sesso HD, Pollak M, et al. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:2618–27.PubMedCrossRefGoogle Scholar
  32. 32.
    Teras LR, Goodman M, Patel AV, Bouzyk M, Tang W, Diver WR, et al. No association between polymorphisms in LEP, LEPR, ADIPOQ, ADIPOR1, or ADIPOR2 and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2009;18:2553–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Pechlivanis S, Bermejo JL, Pardini B, Naccarati A, Vodickova L, Novotny J, et al. Genetic variation in adipokine genes and risk of colorectal cancer. Eur J Endocrinol. 2009;160:933–40.PubMedCrossRefGoogle Scholar
  34. 34.
    Gornick MC, Rennert G, Moreno V, Gruber SB. Adiponectin gene and risk of colorectal cancer. Br J Cancer. 2011;105:562–4.PubMedCrossRefGoogle Scholar
  35. 35.
    Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012;33:547–94.PubMedCrossRefGoogle Scholar
  36. 36.
    Li H, Stampfer MJ, Mucci L, Rifai N, Qiu W, Kurth T, et al. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem. 2010;56:34–43.PubMedCrossRefGoogle Scholar
  37. 37.
    Pinthus JH, Kleinmann N, Tisdale B, Chatterjee S, Lu JP, Gillis A, et al. Lower plasma adiponectin levels are associated with larger tumor size and metastasis in clear-cell carcinoma of the kidney. Eur Urol. 2008;54:866–73.PubMedCrossRefGoogle Scholar
  38. 38.
    Tian YF, Chu CH, Wu MH, Chang CL, Yang T, Chou YC, et al. Anthropometric measures, plasma adiponectin, and breast cancer risk. Endocr Relat Cancer. 2007;14:669–77.PubMedCrossRefGoogle Scholar
  39. 39.
    Saxena A, Chumanevich A, Fletcher E, Larsen B, Lattwein K, Kaur K, et al. Adiponectin deficiency: role in chronic inflammation induced colon cancer. Biochim Biophys Acta. 1822;2012:527–36.Google Scholar
  40. 40.
    Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50:2094–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Jaziri R, Aubert R, Roussel R, Emery N, Maimaitiming S, Bellili N, et al. Association of ADIPOQ genetic variants and plasma adiponectin isoforms with the risk of incident renal events in type 2 diabetes. Nephrol Dial Transplant. 2010;25:2231–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Adams SH. Emerging perspectives on essential amino acid metabolism in obesity and the insulin-resistant state. Adv Nutr. 2011;2:445–56.PubMedGoogle Scholar
  43. 43.
    Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev. 2007;16:2533–47.PubMedCrossRefGoogle Scholar
  44. 44.
    Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363:1346–53.PubMedCrossRefGoogle Scholar
  45. 45.
    Cohen, D. H., Leroith, D. Obesity, type 2 diabetes and cancer: the insulin and insulin-like growth factor connection. Endocr Relat Cancer. 2012. doi: 10.1530/ERC-11-0374.
  46. 46.
    Kanazawa I, Yamaguchi T, Sugimoto T. Serum insulin-like growth factor-I is negatively associated with serum adiponectin in type 2 diabetes mellitus. Growth Horm IGF Res. 2011;21:268–71.PubMedCrossRefGoogle Scholar
  47. 47.
    Brakenhielm E, Veitonmaki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A. 2004;101:2476–81.PubMedCrossRefGoogle Scholar
  48. 48.
    Moon, H. S., Liu, X., Nagel, J. M., Chamberland, J. P., Diakopoulos, K. N., Brinkoetter, M. T. et al. Salutary effects of adiponectin on colon cancer: in vivo and in vitro studies in mice. Gut. 2012. doi: 10.1136/gutjnl-2012-302092.
  49. 49.
    Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867–72.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  1. 1.Department of Hepatobiliary Surgery, The Second Xiangya HospitalCentral South UniversityChangsha CityChina
  2. 2.Department of General SurgeryThe second affiliated hospital of Nan Chang UniversityNanChang CityChina

Personalised recommendations